| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Myles Wolf | Q90101213 |
| Tamara Isakova | Q110282035 | ||
| P2093 | author name string | Orlando M Gutiérrez | |
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 | ||
| FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 | ||
| Mutation of the mouse klotho gene leads to a syndrome resembling ageing | Q24328782 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Phosphate regulation of vascular smooth muscle cell calcification | Q28139908 | ||
| FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization | Q28177435 | ||
| The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency | Q28202356 | ||
| Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production | Q28213962 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Normalization of hemoglobin level in patients with chronic kidney disease and anemia | Q28274269 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice | Q28507303 | ||
| Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action | Q28568880 | ||
| Relationship of phosphorus and calcium-phosphorus product with mortality in CKD | Q81132238 | ||
| The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination | Q81371364 | ||
| Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study | Q81376661 | ||
| Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients | Q81489212 | ||
| Impact of left ventricular hypertrophy on survival in end-stage renal disease | Q93520188 | ||
| Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo | Q28572995 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Prevalence of chronic kidney disease in the United States | Q29614191 | ||
| Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study | Q29614968 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. | Q30372125 | ||
| A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. | Q31147535 | ||
| Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin | Q33562017 | ||
| The emerging role of phosphate in vascular calcification | Q33595584 | ||
| Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients | Q33862661 | ||
| Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? | Q33880308 | ||
| Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 | ||
| Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers | Q33974129 | ||
| Rosuvastatin and cardiovascular events in patients undergoing hemodialysis | Q34016806 | ||
| Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease | Q34017373 | ||
| Effect of dialysis dose and membrane flux in maintenance hemodialysis | Q34165823 | ||
| FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting | Q34227442 | ||
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| Preventing microalbuminuria in type 2 diabetes | Q34552302 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy | Q34648670 | ||
| Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial | Q34690053 | ||
| Phosphorus binders and survival on hemodialysis | Q34907022 | ||
| Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis | Q35086952 | ||
| Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption | Q35840203 | ||
| Vascular calcification mechanisms | Q35972974 | ||
| Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men | Q36153795 | ||
| Pathogenesis of vascular calcification in chronic kidney disease. | Q36192817 | ||
| Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? | Q36665925 | ||
| Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD | Q36667209 | ||
| The mechanism of phosphorus as a cardiovascular risk factor in CKD | Q36677622 | ||
| Endocrine functions of bone in mineral metabolism regulation. | Q36982323 | ||
| Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial | Q37042040 | ||
| Serum phosphorus levels associate with coronary atherosclerosis in young adults | Q37086648 | ||
| Association of serum phosphate with vascular and valvular calcification in moderate CKD. | Q37086670 | ||
| Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. | Q37123248 | ||
| Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. | Q37148473 | ||
| Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease | Q37322636 | ||
| Latest findings in phosphate homeostasis | Q37384718 | ||
| Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial | Q38383699 | ||
| Vascular calcification and cardiovascular function in chronic kidney disease | Q39735035 | ||
| Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study | Q40403628 | ||
| Adenosine triphosphate turnover in humans. Decreased degradation during relative hyperphosphatemia | Q40511555 | ||
| FGF23 is processed by proprotein convertases but not by PHEX. | Q40532892 | ||
| Increased nephron oxygen consumption: potential role in progression of chronic renal disease | Q40815750 | ||
| Current understanding of the molecular actions of vitamin D. | Q40838113 | ||
| Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis | Q43749106 | ||
| Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients | Q44039636 | ||
| Role of dietary phosphorus in the progression of renal failure | Q44071622 | ||
| Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells | Q44173368 | ||
| Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study | Q44278022 | ||
| Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia | Q44414604 | ||
| Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia | Q44493980 | ||
| Kidney disease as a risk factor for recurrent cardiovascular disease and mortality | Q44511551 | ||
| High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients | Q44977753 | ||
| Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. | Q44985964 | ||
| FGF-23 is elevated by chronic hyperphosphatemia | Q45050609 | ||
| Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems | Q45059018 | ||
| Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study | Q45081609 | ||
| Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. | Q45166203 | ||
| Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. | Q45197408 | ||
| Serum phosphate levels and mortality risk among people with chronic kidney disease | Q45198981 | ||
| Activated injectable vitamin D and hemodialysis survival: a historical cohort study | Q45281077 | ||
| Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients | Q46122319 | ||
| Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients | Q46123508 | ||
| Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States | Q46547776 | ||
| Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 | ||
| Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients | Q46631801 | ||
| A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study | Q46635492 | ||
| Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. | Q46680438 | ||
| Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure | Q46726693 | ||
| Relation between serum phosphate level and cardiovascular event rate in people with coronary disease | Q46772376 | ||
| Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats | Q46881133 | ||
| Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans | Q46925293 | ||
| Central control of renal sodium-phosphate (NaPi-2) transporters | Q48134129 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| Cardiovascular disease and subsequent kidney disease | Q50155784 | ||
| Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. | Q52177409 | ||
| Natural history of vascular calcification in dialysis and transplant patients. | Q53618098 | ||
| Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil. | Q54405847 | ||
| FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. | Q54733425 | ||
| Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. | Q54784940 | ||
| The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 | ||
| Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients | Q57221103 | ||
| Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure | Q57224706 | ||
| Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients | Q57226018 | ||
| Calcium acetate control of serum phosphorus in hemodialysis patients | Q57226608 | ||
| Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis | Q57227542 | ||
| Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community | Q57308708 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease | Q57772116 | ||
| Registered Dietitian Time Requirements in the Modification of Diet in Renal Disease Study | Q58402121 | ||
| Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study | Q59575076 | ||
| Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study | Q60777269 | ||
| Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. | Q64975749 | ||
| Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group | Q69167761 | ||
| Serum concentration of 1,25-dihydroxyvitamin D in the human: diurnal variation | Q70112063 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Circadian rhythms of blood minerals in humans | Q70844701 | ||
| Renal toxicity of phosphate in rats | Q71307751 | ||
| Pathogenesis of secondary hyperparathyroidism | Q71612728 | ||
| Clinical and echocardiographic disease in patients starting end-stage renal disease therapy | Q72192935 | ||
| Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture | Q72407567 | ||
| Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis | Q73804043 | ||
| Arterial stiffening and vascular calcifications in end-stage renal disease | Q73914339 | ||
| Inorganic phosphate induces apoptosis of osteoblast-like cells in culture | Q74234072 | ||
| Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease | Q74756562 | ||
| Vascular calcification in chronic kidney disease | Q76380712 | ||
| RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group | Q77807674 | ||
| Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis | Q77814884 | ||
| Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men | Q79298180 | ||
| Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease | Q79337877 | ||
| Correction of anemia with epoetin alfa in chronic kidney disease | Q79363020 | ||
| Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients | Q79478108 | ||
| Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency | Q79485416 | ||
| Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization | Q79811373 | ||
| Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients | Q79947877 | ||
| Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women | Q79995263 | ||
| Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? | Q80186552 | ||
| Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis | Q81098862 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorus | Q674 |
| P304 | page(s) | 705-716 | |
| P577 | publication date | 2009-07-15 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease | |
| P478 | volume | 76 |
| Q45712908 | A balanced view of calcium and phosphate homeostasis in chronic kidney disease |
| Q53288925 | Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. |
| Q37126261 | Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure |
| Q46432103 | Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism |
| Q37542914 | Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons |
| Q37951798 | Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis |
| Q38070709 | Contributions to total phosphorus intake: all sources considered |
| Q33684149 | Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? |
| Q50878659 | Educational nursing intervention to reduce the hyperphosphatemia in patients on hemodialysis. |
| Q30427104 | Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality |
| Q39866881 | FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment |
| Q35156017 | FGF-23: More than a regulator of renal phosphate handling? |
| Q38031216 | FGF-23: the rise of a novel cardiovascular risk marker in CKD. |
| Q37284113 | FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. |
| Q37654689 | FGF23-parathyroid interaction: implications in chronic kidney disease |
| Q35965337 | Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease |
| Q35099518 | Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease |
| Q35145356 | Hemodynamics and function of resistance arteries in healthy persons and end stage renal disease patients |
| Q33770086 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial |
| Q35608435 | Management of hyperphosphataemia in chronic kidney disease-challenges and solutions |
| Q37843788 | Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes |
| Q37871341 | Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers |
| Q33749467 | Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease |
| Q48703205 | Nutritional status evaluated by multi-frequency bioimpedance is not associated with quality of life or depressive symptoms in hemodialysis patients. |
| Q85121247 | Once-Daily Extended-Release Niacin Lowers Serum Phosphorus Concentrations in Patients With Metabolic Syndrome Dyslipidemia |
| Q37948105 | Pharmacotherapy of chronic kidney disease and mineral bone disorder. |
| Q24610674 | Phosphate and FGF-23 |
| Q38049170 | Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate |
| Q42123269 | Phosphorus metabolism in chronic kidney disease |
| Q36612883 | Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria |
| Q84135053 | Proposed controlled trials of phosphate reduction in CKD: which whey should we go? |
| Q90480564 | Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3 |
| Q36234712 | Socio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis. |
| Q82522811 | Targeting hyperphosphatemia: truth or dare |
| Q38137046 | The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats |
| Q92959917 | The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia |
| Q37296494 | The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know |
| Q83955899 | The hypothesis that bone turnover influences FGF23 secretion |
| Q34027561 | The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation |
| Q36963471 | The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy |
| Q36210285 | Update on fibroblast growth factor 23 in chronic kidney disease |
| Q55496554 | Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. |
| Q38878795 | Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. |
Search more.